| |
Press Releases
For Immediate Release
Date: June 07, 2009
Contact: Carlene Simmons, Marketing Communications Manager
Phone: 800.871.8909 ext. 109
FDA Clears Caspofungin (Cancidas®) Susceptibility Testing
for TREK Sensititre® YeastOne®in Vitro Diagnostics (IVD) Product Line
- Caspofungin now available on YeastOne custom-configured plates; YeastOne is
the only microbroth dilution product on the market with five IVD-cleared antifungal
compounds: itraconazole, fluconazole,
5-flucytosine, voriconazole and caspofungin
Cleveland, Ohio — June 07, 2009 – TREK Diagnostic Systems, a Magellan
Biosciences business and premier provider of diagnostic systems and susceptibility
products for microbiology labs, has received clearance from the U.S. Food and Drug Administration
(FDA) to include caspofungin in its line of YeastOne susceptibility products. TREK
will make the drug available on custom YeastOne formats, allowing clinicians to create
the plate that best meets their requirements. The custom format complements TREK’s
standard IVD-cleared YeastOne product (Part No. YO-2V), which contains the four most widely-prescribed
antifungals: itraconazole, fluconazole, 5 flucytosine and voriconazole.
Physicians typically prescribe intravenous caspofungin therapy when other
treatment regimes are not well tolerated or have failed. The first in a new
class of enzyme-inhibiting antifungal agents, caspofungin, is FDA-cleared
for treatment of candidiasis in adults and pediatric patients. Candidiasis
is a fungal infection that can be life-threatening if it becomes systemic.
“This is the second FDA clearance we have received this year for our YeastOne product line,” said
President of Magellan’s diagnostics business, James Whelan. “Last month, we announced
the addition of voriconazole to our standard YeastOne IVD plate. Our goal with IVD susceptibility
products is to increase reportable compounds and treatment options for clinicians. Customers need
plates that allow them to report timely results using a fully reimbursable format. We are committed
to taking our products through the FDA clearance process where feasible and appropriate. Because
pharmaceutical companies use our Sensititre susceptibility system during drug development, we often
get early access to the latest therapeutics and are able to provide clinicians with the widest possible
drug choices. A wide array of cost-effective plate formats that deliver timely and reliable results
not only supports pharmacy cost-control efforts – it improves patient care.”
About the Sensititre YeastOne Product Line
TREK offers a wide range of FDA cleared and research-use-only (RUO) YeastOne
dried microbroth dilution plates with a variety of drug options. The products
provide physicians and researchers with fast, cost-effective, and reliable
results. Plates feature standard 24-hour incubation, easy-to-read colorimetric
endpoints, and on-scale QC ranges, making antifungal susceptibility testing
a viable in-house procedure for virtually any size laboratory.
- YeastOne for IVD
The YeastOne product line received its first FDA
clearance in 2001 and has been widely recognized for accuracy. TREK’s standard IVD YeastOne
plate (Part No. YO-2V) is the only IVD-labeled susceptibility product
that is FDA-cleared for testing Candida species isolates against four
commonly prescribed FDA-cleared antifungal agents: voriconazole, fluconazole,
5-flucytosine and itraconazole.
- YeastOne for RUO
TREK’s standard RUO YeastOne plate (Part No. YO-9*) includes
nine antimicrobics: anidulafungin, amphotericin B, caspofungin, fluconazole,
5 flucytosine, itraconazole, micafungin, posaconazole and voriconazole.
*For
research use only. Not for use in diagnostic procedures.
- Custom YeastOne plates
Labs can customize plates by selecting from
nine antifungal agents, including five cleared antifungal compounds, and
specifying format and drug concentrations to create the best plate for their
particular needs. Small minimum order
quantities allow for better cost and inventory control. To learn more about
custom plates, call customer service toll-free at 800 871-8909. Outside the
US and Canada, dial +44 (0) 1342-318777 or e-mail: mmansfield@trekds.co.uk
About TREK Diagnostic Systems (www.trekds.com)
A Magellan Biosciences
diagnostics business, TREK is a global manufacturer and distributor of automated
systems and consumable products for microbiology-based diagnostic testing
designed to improve patient outcomes. Signature product lines include VersaTREK®, Sensititre®, Vizion®, alamarBlue®, para-JEM®,
YeastOne®, onSite® and TREK Lab Services. TREK is committed to delivering
the highest quality products and services to clinical, pharmaceutical, and
veterinary diagnostic laboratories worldwide.
Cancidas is a registered trademark of Merck & Co., Inc.
For more information, contact Carlene Simmons at 1.800.871.8909 ext. 109 or via e-mail
at csimmons@trekds.com.
###
< back
|
 |